Core Viewpoint - TC BioPharm has successfully closed a public offering, raising $6 million to support its clinical trials and operational expenses [1][2]. Group 1: Offering Details - The public offering was upsized to 6,000,000 American Depository Shares (ADSs) at a price of $1 per ADS, along with Series H warrants [1]. - The Series H warrants have an exercise price of £0.76 per ADS and will expire one year from issuance [1]. - Each ADS represents 200 ordinary shares of the company [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for a clinical trial focusing on relapse/refractory Acute Myeloid Leukemia, market awareness, and ongoing operating expenses [2]. Group 3: Company Overview - TC BioPharm is a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies for cancer treatment, with a focus on acute myeloid leukemia [6]. - The company is recognized as a leader in developing gamma-delta T cell therapies and is the first to conduct phase II/pivotal clinical studies in oncology [6]. - TC BioPharm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, utilizing proprietary allogeneic CryoTC technology [6].
TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering